Kerecis Spins off Virus-Infection-Protection Product Line into Subsidiary Company

Arlington, VA, and Reykjavik, Iceland—October 19, 2020—Kerecis Limited, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, has created Viruxal Limited, a separate subsidiary to continue the research, development and commercialization of its Viruxal tissue-protection technology.

 

“Our patented, fatty-acid-rich fish-skin and wound-spray technologies have proven effective in treating wounds and reducing the risk of infection,” explained G. Fertram Sigurjonsson, founder and CEO of Kerecis. “We’ve now spun off the infection-control portion of our technology into a separate subsidiary.”

Viruxal Limited will focus on over-the-counter applications of the technology in the fight of viral respiratory diseases such as COVID-19. “Kerecis will remain focused on its wound-care and soft-tissue-reconstruction products,” added Sigurjonsson.

For information about Viruxal visit www.viruxal.com.